Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
FGFR Inhibitor
DRUG
2 trials
Sponsors
University Health Network, Toronto
, Zhejiang University
Conditions
Advanced
Bile Duct Carcinoma
Cholangiocarcinoma
Metastatic
Recurrent
Salivary Gland Cancer
Phase 2
Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study
Not yet recruiting
NCT07729917
Zhejiang University
Bile Duct Carcinoma, Cholangiocarcinoma
Start: 2026-08-10
End: 2030-12-31
Target: 240
Updated: 2026-07-28
Unknown Phase
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
Completed
NCT02069730
University Health Network, Toronto
Salivary Gland Cancer, Metastatic, Advanced +1
Start: 2014-06-30
End: 2023-06-30
Updated: 2026-01-08
Related Papers
Abstract P154: Genomic profiling and matched therapy for recurrent or metastatic salivary gland neoplasms. Results from the matched cohort of the GEMS-001 clinical trial
Molecular Cancer Therapeutics
2021-12-01
1 citations
Molecular profiling and targeted agents in recurrent, metastatic salivary gland tumor (R/M SGT) patients (pts) treated at two academic centers.
Journal of Clinical Oncology
2021-05-20
3 citations
Recurrent or metastatic salivary gland tumor (MSGT) patients treated with selinexor, a first in class selective exportin-1 (XPO1) inhibitor.
Journal of Clinical Oncology
2020-05-20
1 citations
Genomic profiling and matched therapy for recurrent or metastatic malignant salivary gland tumors
Annals of Oncology
2018-10-01